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Abstract
Background: It has been suggested that pro-inflammatory cytokine signaling to the brain may contribute to severe
fatigue. We propose that not only the level of circulating cytokines, but also increased reactivity of target cells to
cytokines contributes to the effect of cytokines on behavior. Based on this concept, we assessed the reactivity of
peripheral blood cells to IL-1β in vitro as a novel approach to investigate whether severe fatigue is associated with
increased pro-inflammatory signaling.
Methods: We included 504 soldiers before deployment to a combat-zone. We examined fatigue severity and the
response to in vitro stimulation with IL-1β prior to deployment (T0), and 1 (T1) and 6 months (T2) after deployment.
IL-8 production was used as read-out. As a control we determined LPS-induced IL-8 production. The presence of
severe fatigue was assessed with the Checklist Individual Strength (CIS-20R). Differences in dose–response and the
longitudinal course of IL-1β and LPS-induced IL-8 production and fatigue severity were investigated using repeated
measures ANOVA.
Results: At T2, the group who had developed severe fatigue (n= 65) had significantly higher IL-1β-induced IL-8
production than the non-fatigued group (n= 439). This group difference was not present at T0, but developed over
time. Longitudinal analysis revealed that in the non-fatigued group, IL-1β-induced IL-8 production decreased over
time, while IL-1β-induced IL-8 production in the fatigued group had not decreased. To determine whether the
observed group difference was specific for IL-1β reactivity, we also analyzed longitudinal LPS-induced IL-8
production. We did not observe a group difference in LPS-induced IL-8 production.
Conclusions: Collectively, our findings indicate that severe fatigue is associated with a higher reactivity to IL-1β. We
propose that assessment of the reactivity of the immune system to IL-1β may represent a promising novel method
to investigate the association between behavioral abnormalities and pro-inflammatory cytokine signaling.
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Background
The experience of prolonged severe fatigue after return
from military deployment is a common phenomenon.
The prevalence of severe fatigue in Dutch military
personnel 1 to 4 years after return from deployment to
Cambodia, Rwanda, and Bosnia has been estimated to
be 7.6 to 12.4 times higher than in non-deployed mili-
tary personnel [1]. In addition, the prevalence of chronic
fatigue syndrome (CFS)-like symptoms in US military
personnel 5 years after return from deployment to the
Gulf Region was 6.8 to 9.1 times higher compared to
non-deployed military personnel [2].
It has been suggested that the development of severe
fatigue may result from behavioral consequences asso-
ciated with increased pro-inflammatory signaling [3-7].
An increase in pro-inflammatory signaling may result
from increased levels of circulating pro-inflammatory
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cytokines. Consistent with this notion, increased levels
of circulating pro-inflammatory cytokines have repeat-
edly been observed in individuals with severe fatigue or
CFS compared to non-fatigued individuals [8-13]. How-
ever, not all results of studies on cytokines levels in fa-
tigue are consistent with increased levels of circulating
pro-inflammatory cytokines: decreased or unaltered
levels of pro-inflammatory serum cytokine levels also
have been described in severely fatigued individuals
compared to non-fatigued individuals [3-7].
The response of the body to an inflammatory mediator
or other regulatory mediators does not only depend on
the circulating levels of the specific mediator at a given
moment, but also depends on the sensitivity or reactivity
of the target system to regulation by the specific medi-
ator. This reactivity of the target cells is determined at
the level of the receptor, by receptor number, ligand
binding affinity, and coupling of the receptor to intracel-
lular signaling pathways. In addition, intracellular pro-
cesses downstream of the receptor determine the
reactivity of a cell to regulation by specific mediators
[14]. Thus, an increase in pro-inflammatory signaling
may also result from increased reactivity of target cells
to pro-inflammatory cytokines.
Based on this concept, we assessed IL-1β-induced
cytokine production by peripheral blood cells in vitro to
determine whether severe fatigue is associated with
altered reactivity of immune cells to pro-inflammatory
cytokines. We selected IL-1β because of the existing evi-
dence for a pivotal role of IL-1β signaling in the behav-
ioral consequences of inflammation. For example,
systemic or central administration of IL-1β triggers the
development of sickness behavior in rodents [15]. More-
over, the development of peripheral inflammation-
induced sickness behavior in rodents can be completely
prevented when IL-1 action is blocked [16]. Further-
more, the fatigue symptoms of patients with the chronic
inflammatory disease rheumatoid arthritis were signifi-
cantly reduced after administration of an IL-1-receptor
antagonist [17]. In peripheral blood mononuclear cells,
IL-1β induces the production of pro-inflammatory cyto-
kines and chemokines, including IL-8 [18]. Therefore
altered IL-8 production by peripheral blood mono-
nuclear cells in response to exposure of these cells to IL-
1β is an indicator of altered reactivity of IL-1 receptors
and/or downstream signaling pathways.
We assessed whether soldiers with and without severe
fatigue 6 months after return from deployment to a
combat-zone differed in IL-1β-induced IL-8 production
by peripheral blood cells, as assessed in vitro at 6 months
(T2) after return from deployment. We also investigated
the longitudinal course of IL-1β-induced IL-8 produc-
tion in samples obtained prior to (T0), 1 month (T1),
and 6 months after deployment (T2).
Our results show that soldiers with severe fatigue
showed a higher reactivity to IL-1β at 6 months after re-
turn from military deployment than the non-fatigued
group. This group difference had developed in response
to the deployment. These results indicate that assess-
ment of the reactivity of the immune system to IL-1β
may be a promising novel method to study the associ-




This study was carried out in compliance with the Dec-
laration of Helsinki. The study was approved by the In-
stitutional Review Board of the University Medical
Center Utrecht, the Netherlands. Written informed con-
sent was obtained after a written and verbal description
of the study.
General procedure
This study is part of a prospective cohort study on bio-
logical and psychological aspects of the development of
deployment-related disorders in the Dutch Armed
Forces [19-24]. Military personnel of the Dutch Armed
Forces assigned to a 4-month deployment were included
on a voluntary basis. Their duties during deployment
included combat patrols, clearing or searching buildings,
participation in de-mining operations, and transporta-
tion across enemy territory. Typical combat-zone stres-
sors included enemy fire, armed combat, and combat
casualties. We included participants deployed from 2006
to 2009. Participants were assessed 1 to 2 months prior
to deployment (T0), and approximately 1 (T1) and
6 months (T2) after their return from deployment. Dur-
ing each assessment, participants filled out question-
naires. In addition, a heparinized blood sample was
drawn between 08:00 and 11:30. Heparinized blood was
kept at room temperature.
Participants
A total of 721 participants completed questionnaires and
blood sampling for measurement of IL-1β sensitivity be-
fore deployment (T0). Since we were interested in the
development of severe fatigue in response to deploy-
ment, we excluded 32 (4.4%) participants who already
reported severe fatigue before deployment, resulting in
689 participants at T0. Twelve participants (1.7%) were
not available for follow-up (non-deployed (n= 10);
deceased during deployment (n= 2)). Of the eligible 677
participants after deployment, 504 participants (74.4%)
completed the assessments at T1 and T2.
Participants were divided into groups based on their
level of fatigue at T2, assessed with the Checklist Indi-
vidual Strength (CIS-20R). The used cutoff for the total
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score on the CIS-20R was ≥81 [19]. This cutoff corre-
sponds to the 95th percentile of scores before deploy-
ment within a population of 862 Dutch military
personnel (mean (SD): 45.87 (17.69)).
A total of 65 participants (12.9%) reported severe fa-
tigue at T2 and were therefore included in the fatigued
group. The remaining 439 participants (87.1%) were
included in the non-fatigued group.
Compared to eligible individuals who did complete the
assessments after deployment, dropouts were younger
during deployment (mean (SD): dropouts: 25.89 (6.08);
completers: 28.57 (8.98), t(673): -3.64, P< 0.001). As a result
they had been deployed less often (mean (SD): dropouts:
0.64 (0.93); completers: 0.91 (1.22), t(650): -2.33, P< 0.05)
and were lower ranked χ2 3ð Þ : 13:91; p < :01
 
. There was no
significant difference in educational level between comple-
ters and dropouts χ2 2ð Þ : 4:50; p ¼ :105
 
. In addition, there was
no significant difference in fatigue severity at T0 (mean
(SD): dropouts: 43.54 (14.42); completers: 44.25 (15.33);
t(675): -0.53, P=0.593).
Questionnaires
Level of fatigue over the past 2 weeks was assessed with
the Dutch 20-item Checklist Individual Strength (CIS-20R)
[25]. The questionnaire consists of four subscales: severity
of fatigue, concentration, motivation, and physical activity.
The total fatigue score is the sum score of all items (range,
20 to 140). The questionnaire is well validated and has good
reliability.
Collected demographics and deployment characteristics
included age and rank during deployment, gender, educa-
tional level, number of previous deployments, and use of
medication (non-systemic glucocorticoids (nasal spray or
crème), antihistamines, cholesterol-lowering medications,
and anti-hypertensives). Exposure to deployment-stressors
was assessed with a 13-item checklist during the T1
assessment (available as supplementary material in 22).
IL-1β-reactivity
Whole blood, diluted 1:10 with RPMI-1640 (Gibco, Grand
Island, NY, USA), was stimulated with human interleukin
(IL)-1β (Pepro Tech Inc, Rocky Hill, NJ, USA) for 24 h at
37 °C/5% CO2 in 96-well flat-bottomed plates. The final
concentrations of IL-1β were: 0, 1, 3, 10, 30 ng/mL. IL-1β
doses in this range are frequently used in in vitro experi-
ments in various tissues [26-29]. Supernatants were stored
at −80 °C. In a pilot analysis, the level of IL-6, TNF-a, IL10,
and IL-8 were determined by ELISA (Sanquin, the Nether-
lands). IL-6, TNF-a, IL-10, and IL-8 were selected as initial
read-outs, because they represent characteristic cytokines
of respectively the pro-inflammatory, anti-inflammatory,
and chemoattractive cytokine spectrum. In an initial
screening of samples from 37 individuals it became appar-
ent that IL-1β did not induce IL-10 production. In addition,
screening approximately 750 random samples revealed that
in response to the lowest dose of IL-1β, the TNF-α level
was below the detection limit in 51% of the samples and
IL-6 was not detectable in 11.5% of the samples. Moreover,
after stimulation with 30 ng/mL IL-1β, we did not detect
TNF-a in 15% and IL-6 in 2.5% of the samples. In contrast,
IL-8 appeared to be robustly induced by IL-1β, with only
5.4% of the values below the detection limit after stimula-
tion with 1 ng/mL IL-1β and 0.5% below the detection limit
after stimulation with 30 ng/mL IL-1β. Therefore, we
selected IL-8 as a read-out. Further analyses showed that
there was a robust, dose-dependent increase in IL-8 in re-
sponse to stimulation by IL-1β.
Absolute numbers of monocytes, granulocytes, lym-
phocytes, and CD3+ T-cells were calculated from a total
leukocyte count. To determine the response to LPS,
whole blood was diluted 1:10 with RPMI-1640 (Gibco,
Grand Island, NY, USA), and stimulated with lipopolysac-
charide (LPS, Escherichia Coli 0127:B8, Sigma, final
concentrations 1 ng/mL) for 24 h at 37 °C/5% CO2 in 96-
well flat-bottomed plates. Supernatants were stored at
-80C and IL-8 concentrations were determined using a
multiplex cytokine assay [30]. We used a dose of 1 ng/mL
LPS, since preliminary analysis of a dose–response curve
(0, 0.01, 0.1, and 1 ng/mL LPS) revealed that a plateau in
IL-8 production was reached at a dose of 1 ng/mL LPS.
Statistics
Statistical analyses were conducted using PASW/SPSS
18.0. Differences between groups were considered sig-
nificant at P < 0.05. All continuous variables were tested
for normality and log-transformed when necessary. A
limited number of missing values were present due to
technical and handling problems (<7.5% for each vari-
able). Outliers were removed if z-values were outside the
range of ± 3.29 [31] (<2% for each variable).
Differences between groups in continuous demographic
and deployment characteristics were assessed with t-tests.
Differences in non-continuous demographic variables be-
tween groups were tested with Chi-square (χ2) tests.
Repeated measures ANOVA was used to analyze the
dose–response of IL-8 production after stimulation with
increasing doses of IL-1β at T2. In addition, repeated mea-
sures ANOVA was used to analyze the longitudinal course
of CIS-20R total scores, IL-1β-induced IL-8 production,
non-stimulated IL-8 production, cell subsets, and LPS-
induced IL-8 production. Time was used as within-
subjects factor and group as between-subjects factor. A
Greenhouse-Geisser correction was applied when spher-
icity was violated and E≤ 0.75. A Huyn-Feldt correction
was applied if sphericity was violated and E > 0.75 [31].
Post hoc t-tests with Bonferroni correction were used for
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follow-up of significant effects. In addition, significant
group x time interactions differences were followed by
simple effects analyses [31]. Pearson’s r correlations were
used to investigate associations between IL-1β-induced
IL-8 production and demographic and deployment char-
acteristics for each assessment point. Demographic and
deployment characteristics that significantly correlated
with IL-8 production were included as covariates in the
repeated measures ANOVA. Non-transformed data are
presented in all tables and figures.
Results
Participant characteristics and longitudinal course of
fatigue symptoms
Our aim was to investigate whether participants with
and without severe fatigue after return from military de-
ployment differed in IL-1β reactivity of peripheral blood
cells in vitro. For that purpose, we decided to use a di-
chotomous approach in which participants were divided
into groups with and without severe fatigue (that is, a
score above or below the cutoff of 81 on the CIS-20R
total score) at 6 months after return (T2).
We first analyzed the difference in the longitudinal
course of symptoms (Figure 1). As expected, we
observed a significant difference in the longitudinal
course of fatigue symptoms between the fatigued and
non-fatigued group (time: F(1.98, 970.51): 138.17, P < 0.001;
group: F(1,491): 283.73, P < 0.001; interaction effect time x
group: F(1.98, 970.51): 118.40, P < 0.001). To further inter-
pret this result, we analyzed the longitudinal course of
symptom development for both groups separately. The
participants with severe fatigue at T2 showed a strong
increase in fatigue severity after deployment compared
to fatigue levels at T0. Moreover, the fatigue severity at
T2 had continued to increase compared one month after
deployment (T1) (time: F(2, 128): 89.844, P < 0.001; change
from T0-T1: P< 0.001, T0-T2: P< 0.001, T1-T2: P< 0.001).
The non-fatigued group had slightly increased fatigue
questionnaire scores at T1 compared to T0. However,
their questionnaire scores had returned to baseline level
at T2 (time: F(1.97, 843.02): 13.123, P<0.001; change from
T0-T1: P<0.001, T0-T2: P= 0.163, T1-T2: P< 0.05).
Interestingly, although participants with severe fatigue
before deployment (T0) were excluded from the ana-
lyses, participants with severe fatigue at T2 had higher
fatigue questionnaire scores than the non-fatigued group
at all assessment points (all time-points: P < 0.001).
We did not observe any significant group differences
in demographic and deployment characteristics between
the fatigued and non-fatigued participants (Table 1).
IL-1β-induced IL-8 production 6 months after deployment
We first investigated whether the fatigued and non-
fatigued group differed in IL-1β-induced IL-8 production
6 months after return from deployment. For this pur-
pose, we analyzed group differences in the dose–
response curve for IL-1β-induced IL-8 production in
cultures of whole blood collected at the assessment
6 months after deployment (T2). Repeated measures
ANOVA showed that IL-1β induced a dose-dependent
increase in IL-8 production in both groups (dose: F(2.00,
924.02): 602.82, P < 0.001). Interestingly, the dose–re-
sponse curve of IL-1β-induced IL-8 production differed
between the groups (group: F(1,461): 4.55, P < 0.01; dose x
group: F(2.00, 924.02): 7.94, P < 0.001) (Figure 2). Post hoc
tests for group differences in IL-8 production for each
dose of IL-1β revealed that the fatigued group had sig-
nificantly higher IL-8 production than the non-fatigued
group after administration of 1 ng/mL (P < 0.05), 3 ng/
mL (P < 0.05), 10 ng/mL (P < 0.01), and 30 ng/mL IL1β
(P < 0.01). The group difference at 10 ng/mL and 30 ng/
mL IL-1β remained significant after applying a Bonfer-
roni correction (significant P value αð Þ ¼ 0:05=5 ¼ :01Þ.
The observed difference in the dose–response curve of
IL-1β-induced IL-8 production between the fatigued and
non-fatigued group was not paralleled by significant
group differences in the number of monocytes 6 months
after deployment (t(470): 0.30, P= 0.767), granulocytes
(t(468): -1.48, P= 0.140), lymphocytes (t(468): -0.65,
P= 0.514), or CD3+ T-cells (t(462): -0.64, P= 0.525) at T2.
Figure 1 Dose–response curves for IL-1β-induced IL-8
production 6 months post-deployment for the fatigued and
non-fatigued group. Whole blood samples obtained 6 months
after deployment (T2) from participants assigned to the fatigued
group (black circles, n= 62) and non-fatigued group (white squares,
n= 401) were stimulated for 24 h with increasing concentrations of
IL-1β. The amount of IL-8 in the culture supernatant was measured
by ELISA. IL-1β induced a dose-dependent increase in IL-8
production in both groups (dose: F(2.00, 924.02): 602.82, P< 0.001), but
the dose–response curve differed between the two groups (group: F
(1,461): 4.55, P< 0.01; dose x group: F(2.00, 924.02): 7.94, P< 0.001). After
applying Bonferroni correction, the fatigued group had significantly
higher IL-8 production than the non-fatigued group after
administration of 10 ng/mL (P< 0.01) and 30 ng/mL IL1β (P< 0.01).
Data are presented as mean± SEM. #P< 0.05, significant before
Bonferroni correction, but not after Bonferroni correction, **P< 0.01,
significant after Bonferroni correction.
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Longitudinal course of IL-1β-induced IL-8 production
We investigated whether the higher IL-1β -induced IL-8
production in the fatigued group was already present prior
to deployment or whether the observed group difference
developed over time. For that purpose, we compared the
longitudinal course of IL-1β-induced IL-8 production be-
tween the fatigued and non-fatigued group.
At T2, we observed the largest group difference in IL-
1β-induced IL-8 production between the fatigued and
non-fatigued group after stimulation with 30 ng/mL
IL-1β. Therefore, we selected this dose for these sub-
sequent analyses.
We observed a significant difference in the longitu-
dinal course of IL-1β-induced IL-8 production be-
tween the fatigued and non-fatigued group (Figure 3;
time: F(1.96; 794.68): 2.60, P = 0.076; group: F(1,406): 5.27,
P < 0.05; time x group: F(1.96, 794.68): 4.30, P < 0.05). To
further interpret this result, we analyzed the longitudinal
course of IL-1β-induced IL-8 production for both groups
separately. IL-1β-induced IL-8 production of the non-
fatigued group decreased after deployment (time: F(1.96,
690.66): 13.57, P<0.001). Both at T1 and T2, IL-1β-induced
IL-8 production in the non-fatigued group was significantly
lower than at T0 (change from T0-T1: P<0.001; T0-T2:
P<0.001; T1-T2: P=1.000). In contrast, the amount of IL-
1β-induced IL-8 production of the fatigued group did not
significantly change over time, and if anything tended to in-
crease (time: F(1.80, 97.19): 2.30, P=0.111).
We also analyzed whether the actual amount of IL-
1β-induced IL-8 production differed between the fati-
gued and non-fatigued group at the three time points
tested. Post hoc t-tests with Bonferroni correction
(significant P value (α) = .05/3 = 0.016) revealed that
the IL-8 production of the fatigued and non-fatigued
group did not differ at T0 (P = 0.867) and T1
(P= 0.062). As already described, the IL-8 production
of the fatigued and non-fatigued group did signifi-
cantly differ at T2 (P < 0.01).
Table 1 Characteristics of the fatigued and non-fatigued group
Fatigued group (n=65) Non-fatigued group (n=439) P value
Age during deployment 29.29 (9.19) 28.47 (8.96) 0.490
Previous deployments (n) 1.05 (1.31) 0.89 (1.20) 0.320
Deployment stressors (n) 5.53 (2.46) 4.98 (2.92) 0.106
Gender 0.667
Male 60 (92.3%) 398 (90.7%)
Female 5 (7.7%) 41 (9.3%)
Rank 0.454
Soldiers 20 (30.8%) 179 (40.8%)
Corporals 13 (20.0%) 84 (19.1%)
Non-commissioned officers 20 (30.8%) 112 (25.2%)
Officers 12 (18.5%) 64 (14.6%)
Education 0.744
Low 23 (35.9%) 170 (39.3%)
Middle 32 (50.0%) 215 (49.7%)
Higher 9 (14.1%) 48 (11.1%)
Data represent mean (standard deviation) or frequency (percentage).
Figure 2 Longitudinal course of fatigue questionnaire scores
for the fatigued and non-fatigued group. Longitudinal course of
CIS-20R total scores for the severely fatigued group (black circles,
n= 65) and non-fatigued group (white squares, n= 428). Fatigue
severity was assessed before deployment (T0) and 1 month (T1) and
6 months (T2) after return from deployment. The longitudinal course
of CIS-20R scores differed between the two groups (time: F(1.98,
970.51): 138.17, P< 0.001; group: F(1,491): 283.73, P< 0.001; interaction
effect time x group: F(1.98, 970.51): 118.40, P< 0.001). However,
participants with severe fatigue at T2 had higher fatigue
questionnaire scores than the non-fatigued group at all assessment
points (T0: P< 0.001, T1: P< 0.001, T2: P< 0.001). Data are presented
as mean± SEM. ***P< 0.001.
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The observed difference in the longitudinal course of
IL-1β-induced IL-8 production between the fatigued and
non-fatigued group was not paralleled by significant
group differences in the longitudinal course of the num-
ber of monocytes, granulocytes, lymphocytes, or CD3+
T-cells over time (Table 2).
Longitudinal course of LPS-induced IL-8 production
Next, we addressed the question whether the observed
difference in the longitudinal course of IL-8 production
between fatigued and non-fatigued individuals is specific
for IL-1β-signaling or represents a general group differ-
ence in the capacity to produce IL-8. To that end, we
compared the longitudinal course of LPS-induced IL-8
production between the fatigued and non-fatigued
group. The data presented in Figure 4 demonstrates that
LPS-induced IL-8 production did not change over time
(F(1.90, 934.51): 1.87, P= 0.157). Moreover, there were no
significant differences between the fatigued and non-
fatigued group (group: F(1,439): 0.36, P= 0.551; interaction
group x time: F(1.90, 934.51): 0.01, P= 0.900).
Influence of demographic and deployment characteristics
To ascertain that our results were not influenced by
confounding factors, we examined correlations between
demographic and deployment characteristics and IL-1β-
induced IL-8 production for each assessment point
separately (Table 3). Demographic and deployment char-
acteristics that correlated significantly with IL-8 produc-
tion on at least one assessment point were subsequently
included as covariates in our analyses. After inclusion of
age, rank, educational level, and the number of reported
deployment stressors in the analysis, the longitudinal
course of Il-1β induced IL-8 production remained sig-
nificantly different between fatigued and non-fatigued
individuals (time: F(1.98, 745.47): 9.60, P < 0.001; time x
group interaction: F(1.94, 745.47): 3.89, P < 0.05; group:
F(1,376): 5.65, P < 0.05).
Discussion
This study was designed based on the concept that the
response of the body to a regulatory mediator is not only
determined by the concentration of the mediator, but
also by the reactivity of the target cells to regulation by a
particular mediator [14]. Our findings indicate that as-
sessment of the reactivity of immune cells to IL-1β
in vitro may represent a promising novel approach to
investigate the relation between severe fatigue and pro-
inflammatory cytokine signaling. Fatigue and IL-1β-
induced IL-8 production by peripheral blood cells
in vitro were assessed in a unique longitudinal prospect-
ive design within a large cohort of soldiers (n= 504)
measured before, and at two time-points after deploy-
ment to a combat zone in Afghanistan. None of the
included participants reported severe fatigue prior to the
deployment, and therefore the observed effects are most
likely associated with the development of severe fatigue
in response to the deployment.
At 6 months after return from military deployment,
the participants with severe fatigue had higher IL-1β-
Figure 3 Longitudinal course of IL-1β-induced IL8-production
for the fatigued and non-fatigued group. Whole blood samples
obtained from participants assigned to the fatigued group (black
circles, n= 55) and non-fatigued group (white squares, n= 353) were
stimulated for 24 h with 30 ng/mL IL-1β. The amount of IL-8 in the
culture supernatant was measured by ELISA, at the assessments
before deployment (T0), and 1 month (T1) and 6 months (T2) after
return from deployment. The longitudinal course of IL-1β-induced
IL-8 production differed between the two groups (time: F(1.96; 794.68):
2.60, P= 0.076; group: F(1,406): 5.27, P< 0.05; time x group: F(1.96: 794.68):
4.30, P< 0.05). The IL-1β-induced IL-8 production of the non-fatigued
group decreased over time (time: F(1.96, 690.66): 13.57, P< 0.001). In
contrast, the amount of IL-1β-induced IL-8 production of the
fatigued group did not significantly change over time (time: F(1.80,
97.19): 2.30, P= 0.111). IL-1β-induced IL-8 production significantly
differed between the fatigued and non-fatigued group at T2
(P< 0.01), but not at T0 (P= 0.867) or T1 (P= 0.062). Data are
presented as mean± SEM. **P< 0.01.
Table 2 Differences in the longitudinal course of various cell subsets between the fatigued and non-fatigued group
Time effect Group effect Group x time effect
Monocytes F = 16.91, P< 0.001 F = 0.83, P= 0.362 F = 0.94, P= 0.388
Granulocytes F = 5.88, P< 0.05 F = 0.23, P= 0.635 F = 2.67, P= 0.070
Lymphocytes F = 5.93, P< 0.05 F = 2.37, P= 0.095 F = 2.15, P= 0.144
T-cells (CD3+) F = 2.74, P= 0.067 F = 2.03, P= 0.133 F = 0.46, P= 0.497
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induced IL-8 production than the non-fatigued parti-
cipants, indicating that the peripheral blood cells of
fatigued participants had a higher reactivity to IL-1β
than those of the non-fatigued group. The observed
group-difference in IL-1β-induced IL-8 production was
specifically associated with a group difference in the
reactivity of peripheral blood cells to stimulation with
IL-1β, because we did not observe a group difference in
LPS-induced IL-8 production. In addition, the increased
IL-1β-induced IL-8 production in the fatigued group
could not be attributed to group differences in the cellu-
lar composition of the peripheral blood.
Investigation of the longitudinal course of IL-1β-
induced IL-8 production revealed that the group differ-
ence in IL-1β reactivity between participants with and
without severe fatigue after return from deployment was
not a pre-existing characteristic, but had developed over
time. The IL-1β-induced IL-8 production of non-
fatigued participants had decreased 1 and 6 months after
deployment compared to the assessment before deploy-
ment. This finding indicates that the leukocytes of
non-fatigued participants had become less reactive to
stimulation with IL-1β over time. In the group of partici-
pants with severe fatigue 6 months after deployment, we
did not observe this decrease in IL-1β-induced IL-8 pro-
duction over time.
During deployment to Afghanistan the participants in
this study encountered a variety of stressors, such as
armed combat, improvised explosive devices (IEDs), mor-
tar attacks, and witnessing colleagues or civilians being
injured or killed as a result. Given the severity of these de-
ployment stressors, we interpret the 4-month deployment
as prolonged stress. We did not include a non-deployed
control group and therefore, we cannot conclude that the
observed changes in fatigue and IL-1β-induced cytokine
production result from the stress of the deployment. How-
ever, it is unlikely that the observed effects can be attribu-
ted to aspecific time-effects such as the year or season of
assessment, since we included military personnel in sev-
eral subsequent cohorts between 2006 and 2009.
It has been reported previously that severe or chronic
stress, such as expected to occur during deployment,
results in increased levels of circulating pro-
inflammatory cytokines [32], up-regulated expression of
genes with NFκB response elements and down-regulated
expression of genes with GR response elements in leuko-
cytes [33,34]. In the current study, the participants who
did not develop fatigue 6 months after deployment
showed a decrease in their reactivity to IL-1β in vitro
after return from deployment. Interestingly, in a previ-
ous study the up-regulation of gene expression with
NFκB response elements in chronically stressed indivi-
duals was paralleled by increased serum IL-1RA, which
could decrease IL-1β capacity [34]. These data indicate
that in periods of severe or chronic stress, adaptive
mechanisms may develop to reduce IL-1 reactivity. Our
finding that the IL-1β-induced IL-8 production in the
participants with severe fatigue after deployment did not
decrease over time could indicate that these participants
have adapted less well to the stress experienced during
the deployment.
At present, the underlying mechanism for the
observed higher IL-1β-induced IL-8 production in
Table 3 Pearson’s correlations between IL-8 production
after stimulation with IL-1β and demographic and
deployment characteristics
IL-8 at T0 IL-8 at T1 IL-8 at T2
Age −0.132a −0.045 −0.208b
Gender 0.078 −0.064 0.021
Previous deployments (n) −0.035 −0.016 −0.036
Rank −0.167b −0.002 −0.160c
Educational level −0.123c 0.021 −0.080
Medication use (y/n) 0.001 0.026 0.001
Deployment stressors (n) 0.149c 0.063
Injury during deployment (y/n) −0.065 0.032
IL-8 production after stimulation with 30 ng/mL IL-1β was assessed before





Figure 4 Longitudinal course of LPS-induced IL8-production for
the fatigued and non-fatigued group. Whole blood samples
obtained from participants assigned to the fatigued group (black
circles, n= 53) and non-fatigued group (white squares, n= 388) were
stimulated for 24 h with 1 ng/mL LPS and IL-8 levels in the culture
supernatant were quantified. Samples were collected before
deployment (T0), and 1 month (T1) and 6 months (T2) after return
from deployment. The amount of LPS-induced IL-8 production did
not change over time and there were no significant differences
between the fatigued and non-fatigued group (time: F(1.90, 934.51):
1.87, P= 0.157; group: F(1,439): 0.36, P= 0.551; time x group: F(1.90,
934.51): 0.10, P= 0.900). Data are presented as mean± SEM.
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participants with severe fatigue after deployment as
compared to the non-fatigued group remains unknown.
It is known that activation of the transcription factor
NFκB, in combination met NF-IL6, is essential and suffi-
cient to induce up-regulation of IL-8 expression after
stimulation with IL-1β [35]. LPS-induced Il-8 production
is also dependent on activation of NFκB, but in this case
in combination with AP-1 [35]. Thus, IL-1β and LPS
both induce IL-8 via transcription factor NFκB, but in
addition use separate other transcription factors. There-
fore it is possible that the group difference in IL-1β-
induced IL-8 production and not LPS-induced IL-8 pro-
duction is mediated by a preferential activation of NF-IL6
in the fatigued group after stimulation with IL-1β. It is also
possible that the mechanism(s) involved in the develop-
ment of the group difference in IL-1β reactivity is located
upstream of transcription factor activation, that is, at the
level of IL-1 receptor expression and/or signaling. The type
I IL-1 receptor (IL-1RI) mediates the biological effects of
IL-1α and IL-1β [18]. The type II IL-1 receptor (IL-1RII)
binds IL-1α and IL-1β with high affinity, but does not sig-
nal: it functions as a ‘decoy’ receptor, which prevents signal
transduction via IL-1RI and thereby negatively regu-
lates IL-1 signaling [18]. The higher response to IL-1β in
the fatigued group compared to the non-fatigued group
may hypothetically have resulted from higher IL-RI levels,
lower IL-1RII levels, or higher IL-1RI signaling to down-
stream targets such as the transcription factors mentioned
above.
In addition, it is possible that IL-1 receptor antagonist
(IL-1RA) contributes to the observed group difference in
IL-1β reactivity 6 months after deployment. IL-1RA can
negatively regulate IL-1β signaling, since IL-1RA binding
to IL-1RI does not elicit signal transduction, but inhibits
activation of the receptor by IL-1β [36]. It is possible
that the fatigued group had lower levels of circulating
IL-1RA than the non-fatigued group at 6 months after
deployment. Miller et al. [34] observed that mean serum
IL-1RA levels in individuals with chronic caregiver stress
were 450 pg/mL, while mean serum IL-1RA levels of
non-stressed healthy controls were 200 pg/mL. On the
basis of these data, we expect that serum IL-1RA levels
in our participants are likely to be in the 200 to 450 pg/mL
range. The final concentration of IL-1RA in our whole
blood culture system (final whole blood dilution=1:20) is
therefore expected to be 10 to 22.5 pg/mL. However, a 10-
to 100-fold excess of IL-1RA is necessary to block
the binding of IL-1β to the IL-1R [37]. Therefore, the
expected IL-1RA levels in our in vitro cultures are
probably too low to block the effects of the dose of
IL-1β we used. In addition, if group differences in the
level of the competitive inhibitor IL-1RA were respon-
sible for the observed group difference in IL-1β-induced
IL-8 production, the largest group differences would be
expected at the lower doses of IL-1β, instead of at the
highest doses of IL-1β.
We observed that the peripheral blood cells of the fati-
gued participants reacted differently to stimulation with
a pro-inflammatory cytokine, that is, IL-1β, in vitro. It
remains to be determined whether the observed group
difference in reactivity to IL-1β in vitro is also present
in vivo. In rodents it has been shown that cytokine levels
in the brain are the mirror image of cytokine levels in
the periphery [15]. For example, peritoneal administra-
tion of IL-1β in rats up-regulate mRNA expression of
various pro-inflammatory cytokines in the brain [38].
Future research should investigate whether differences
in brain responses to cytokines contribute to the devel-
opment of fatigue.
A limitation of the current study is that we did not
formally investigate the presence of medical conditions
that may have influenced the IL-1β-sensitivity of periph-
eral blood cells or the experienced levels of fatigue.
However, participants were physically fit for military de-
ployment and therefore the presence of major medical
conditions prior to deployment is highly unlikely. In
addition, the presence of injuries after deployment and
medication use during the three assessments was very
limited. Moreover, medication use and sustained injuries
did not significantly correlate with IL-1β-induced IL-8
production. It thus seems highly unlikely that the pres-
ence of medical conditions influenced our results.
We are the first to report that the response of peripheral
blood cells to IL-1β in vitro differs between soldiers with
and without severe fatigue 6 months after return from de-
ployment. Six months after return from deployment, the
group who had become severely fatigued had higher IL-
1β-induced IL-8 production than the non-fatigued group.
When analyzing the longitudinal course of IL-1β reactiv-
ity, we observed that this group difference had developed
in response to the deployment, since only in the non-
fatigued group the IL-1β-induced IL-8 production had
decreased after deployment. These findings indicate that
investigating the reactivity of the immune system to
stimulation with IL-1β is a promising novel method to
study the association between behavioral abnormalities
and pro-inflammatory cytokine signaling.
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